Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents Press Releases | 10 September 2021 PR-Servier-Neurochlore-Bumetanide Phase 3 ResultsTélécharger Past research Clinical trials News Press Releases Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents 10 September 2021
